Levemex Syrup contains Levetiracetam (NA) as its active ingredient and is indicated for the adjunctive treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam is an antiepileptic agent that modulates synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure propagation. Levemex Syrup offers a convenient oral liquid formulation, facilitating accurate dosing especially in pediatric and geriatric populations or patients with swallowing difficulties. It is rapidly absorbed with a bioavailability close to 100%, and is minimally metabolized by the liver, reducing the risk of drug interactions. The dosage should be individualized based on patient response and tolerability, with gradual titration recommended to minimize adverse effects. Common side effects include somnolence, dizziness, fatigue, and behavioral changes such as irritability or agitation. Caution is advised in patients with renal impairment, and dose adjustments may be necessary. Levemex Syrup should be used under strict medical supervision, with regular monitoring to assess efficacy and safety. It is contraindicated in patients with known hypersensitivity to Levetiracetam or any of the syrup excipients.